<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PLASMA-LYTE 56 AND DEXTROSE- dextrose monohydrate, sodium chloride, potassium acetate and magnesium acetate tetrahydrate injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>PLASMA-LYTE 56 and 5% Dextrose Injection <br>(Multiple Electrolytes and Dextrose Injection, Type 1, USP) <br>in VIAFLEX Plastic Container</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_inv-a40c337f-e0be-4bcc-b2ef-a1c3ecbdb2b0"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP, 234 mg Sodium Chloride, USP (NaCl); 128 mg Potassium Acetate, USP (C<span class="Sub">2</span>H<span class="Sub">3</span>KO<span class="Sub">2</span>); and 32 mg Magnesium Acetate, Tetrahydrate (C<span class="Sub">4</span>H<span class="Sub">6</span>MgO<span class="Sub">4</span>•4H<span class="Sub">2</span>O). It contains no antimicrobial agents. pH 5.0 (4.0 to 6.5). The pH is adjusted with hydrochloric acid.</p>
<div class="Figure">
<a name="id263"></a><img alt="Structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85c08b62-8de0-42d2-8cdc-fe42e6b605d7&amp;name=image-01.jpg">
</div>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 40 mEq sodium, 13 mEq potassium, 3 mEq magnesium, 40 mEq chloride, and 16 mEq acetate. The osmolarity is 363 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. The caloric content is 170 kcal/L. </p>
<p>The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_inv-31c11dca-8913-4580-a1d2-ffe9bd5c118a"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) has value as a source of water, electrolytes, and calories. It is capable of inducing <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> depending on the clinical condition of the patient. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) produces a metabolic alkalinizing effect. Acetate ions are metabolized ultimately to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water, which requires the consumption of hydrogen cations.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_inv-16e62d5d-5c5f-4bc3-89a9-ae6a2fe19069"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_inv-8bfaa949-d090-4b46-9de4-5f3f4dc84a68"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PLASMA -LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) must not be used in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_inv-9780582c-9657-4750-b3e3-3d4b3b85f016"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not indicated for the primary treatment of severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/infusion reactions, including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, have been reported with PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). </p>
<p>Stop the infusion immediately if signs or symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> develop, such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>. Appropriate therapeutic countermeasures must be instituted as clinically indicated.  </p>
<p>Solutions containing dextrose should be used with caution, if at all, in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to corn or corn products.  </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. </p>
<p>Depending on the volume and rate of infusion, the intravenous administration of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> resulting in dilution of serum electrolyte concentrations, <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, congested states, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> or acid-base imbalance. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> causing congested states with peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> is directly proportional to the electrolyte concentrations of the injection. </p>
<p>Monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with particular caution, if at all, to hypervolemic or overhydrated patients. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with particular caution, if at all, to patients with conditions that may cause <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
<p>Solutions containing magnesium should be used with caution, if at all, in patients with <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span> or conditions predisposing to <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>, including but not limited to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or magnesium therapy such as for <span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with particular caution, if at all, to patients with <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> or at risk for <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>. Excess administration of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can result in <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not indicated for the treatment of hypochloremic <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span> and should be used with caution, if at all, in patients with hypochloremic <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not protein-bound) calcium. PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with particular caution, if at all, to patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with particular caution, if at all, to patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> or conditions predisposing to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (such as severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or adrenocortical insufficiency, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or extensive tissue injury or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>) and in patients with cardiac disease. </p>
<p>In patients with diminished renal function, administration of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in sodium and/or potassium or magnesium retention. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bcd03a97-30c7-40fd-88cf-0f355585caa9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_329e23f8-6c35-4ff8-ad32-65459baaad6e"></a><a name="section-6.1"></a><p></p>
<h2>General  </h2>
<p class="First">Do not connect flexible plastic containers in series in order to avoid <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to possible residual air contained in the primary container. Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.</p>
<p>Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> if the residual air in the container is not fully evacuated prior to administration. </p>
<p>Use of a vented intravenous administration set with the vent in the open position could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span>. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution in patients with overt or <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">subclinical diabetes</span> mellitus. </p>
<p>In order to avoid <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> the infusion rate should not exceed the patient’s ability to utilize glucose. </p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> has been implicated in increasing cerebral ischemic <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> and impairing recovery after acute <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic strokes</span>.  Caution is recommended in using dextrose-containing solutions in such patients. </p>
<p>Early <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has been associated with poor outcomes in patients with severe <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>. Dextrose-containing solutions should, therefore, be used with caution in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, in particular during the first 24 hours following the <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.  </p>
<p>If <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> occurs, the rate of dextrose administration should be reduced and/or insulin administered, or the insulin dose adjusted. </p>
<p>For risk of hyper- and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in newborns, see <a href="#i4i_pediatric_use_id_inv-573105a7-550e-4eb3-a73d-dfc79163afe9">Pediatric Use</a>. </p>
<p>PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a hyper-osmotic solution, having an osmolarity of 363 mOsmol/L (calc). Administration of hypertonic solutions may cause venous irritation, including <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>. Hyperosmolar solutions should be administered with caution, if at all, to patients with hyperosmolar states.</p>
<p>The administration of acetate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_c50d5aee-5b82-4dae-a6da-aa33ddb23e3d"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution is advised when administering PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients treated with drugs that may increase the risk of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, such as corticosteroids. </p>
<p>Caution is advised when administering PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients treated with drugs for which renal elimination is pH dependent. Due to its alkalinizing effect (formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>), PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may interfere with the elimination of such drugs. </p>
<dl>
<dt>•</dt>
<dd>Renal clearance of acidic drugs such as salicylates and barbiturates may be increased. </dd>
<dt>•</dt>
<dd>Renal clearance of alkaline drugs, such as sympathomimetics (e.g., ephedrine, pseudoephedrine), quinidine, and dextroamphetamine (dexamphetamine) sulfate, may be decreased. </dd>
</dl>
<p>Renal clearance of lithium may also be increased. Caution is advised when administering PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients treated with lithium. </p>
<p>Because of its potassium content, PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be administered with caution in patients treated with agents or products that can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> or increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), with ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine.  Administration of potassium in patients treated with these medications can produce severe and potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_inv-16029f44-58a3-44bc-aa47-fde6a13bad80"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fd8b9368-b28e-4084-9fe2-9b354833cc39"></a><a name="section-6.3.1"></a><p></p>
<h3>Pregnancy Category C </h3>
<p class="First">There are no adequate and well controlled studies with PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pregnant women and animal reproduction studies have not been conducted with this drug. Therefore, it is not known whether PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman. PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be given during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_3587a0e8-1de0-4f02-a192-ce26a831ba0c"></a><a name="section-6.4"></a><p></p>
<h2>Labor and Delivery </h2>
<p class="First">Intrapartum maternal intravenous infusion of glucose-containing solutions may produce maternal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> with subsequent fetal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and fetal <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> as well as rebound <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in the neonate.  Fetal <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> can result in increased fetal insulin levels which may result in <span class="product-label-link" type="condition" conceptid="23034" conceptname="Neonatal hypoglycemia">neonatal hypoglycemia</span> following delivery. Consider the potential risks and benefits for each specific patient before administering PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_inv-0a8cd260-3cf2-49ae-89e9-c9f83456a5bc"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is present in human milk. Because many drugs are present in human milk, caution should be exercised when PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_inv-573105a7-550e-4eb3-a73d-dfc79163afe9"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The use of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients is based on clinical practice (see <a href="#i4i_dosage_admin_id_inv-5a19c18c-3f39-48fd-9ad0-cdbd3507e154">DOSAGE AND ADMINISTRATION</a>). </p>
<p>Newborns – especially those born premature and with low birth weight – are at increased risk of developing hypo- or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in the newborn can cause prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> has been associated with <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span>, late onset bacterial and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="373766" conceptname="Retinopathy of prematurity">retinopathy of prematurity</span>, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4283942" conceptname="Bronchopulmonary dysplasia of newborn">bronchopulmonary dysplasia</span>, prolonged length of hospital stay, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.    </p>
<p>Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.  </p>
<p>The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.  <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> can lead to <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Therefore, acute symptomatic <span class="product-label-link" type="condition" conceptid="4047765" conceptname="Hyponatremic encephalopathy">hyponatremic encephalopathy</span> is considered a medical emergency.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_inv-564db8a3-41f8-41a5-b88c-bea852143c72"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_inv-4f17a9ee-f755-4b49-ad4a-03b9f0b45161"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b8a4ac8-146e-437f-9573-b2b0793d3ffb"></a><a name="section-7.1"></a><p></p>
<h2>Post-marketing Adverse Reactions</h2>
<p class="First">The following adverse reactions have been reported with PLASMA-LYTE products with Dextrose. Adverse reactions are listed by MedDRA System Organ Class (SOC), then by Preferred Term in order of severity, where feasible.</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/infusion reactions, including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, and the following manifestations: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">Hyperemia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">Cold sweat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> <br>
</dd>
<dt>•</dt>
<dd>Metabolism and Nutrition Disorders:  <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span><br>
</dd>
<dt>•</dt>
<dd>General Disorders and Administration Site Conditions:  Infusion site reactions (e.g., <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span>)</dd>
</dl>
<p>Other adverse reactions, reported with PLASMA-LYTE products are:</p>
<dl>
<dt>•</dt>
<dd>Other manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/infusion reactions: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">Respiratory rate</span> increased, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">Feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">Piloerection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span><br>
</dd>
<dt>•</dt>
<dd>Infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>   </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b9a90068-4e40-4d27-8eee-64297e4068bb"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Excessive administration of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may lead to <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">Metabolic alkalosis</span> may be accompanied by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> as well as a decrease in ionized serum calcium and magnesium.  </p>
<p>An excessive volume of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may lead to <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> with a risk of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired.  </p>
<p>Excessive administration of potassium may lead to the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, especially in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Excessive administration of magnesium may lead to <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>. </p>
<p>Excessive administration of a dextrose-containing solution may lead to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, hyperosmolarity, osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>When assessing an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, any additives in the solution must also be considered.</p>
<p>The effects of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may require immediate medical attention and treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_inv-5a19c18c-3f39-48fd-9ad0-cdbd3507e154"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.</p>
<p>As directed by a physician. Dosage, rate, and duration of administration are to be individualized and dependent upon the indication for use, the patient’s age, weight, concomitant treatment and clinical condition of the patient as well as laboratory determinations. </p>
<p>The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">low weight</span> infants, because of the increased risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.  The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.</p>
<p>After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  Use of a final filter is recommended during administration of all parenteral solutions, where possible.</p>
<p>Do not administer unless the solution is clear and the seal is intact. </p>
<p>Additives may be incompatible with PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is appropriate. After addition, check for possible color change and/or the appearance of precipitates, insoluble complexes or crystals. </p>
<p>The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible must not be used. When introducing additives to PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP), aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_inv-6e7d1ae6-d82e-4495-a083-eb31f38db87d"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First">Code</p></td>
<td class="Toprule" align="center"><p class="First">Size (mL)</p></td>
<td class="Toprule" align="center"><p class="First">NDC</p></td>
</tr>
<tr>
<td align="center"><p class="First">2B2573</p></td>
<td align="center"><p class="First">500</p></td>
<td align="center"><p class="First">NDC 0338-0147-03</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First">2B2574</p></td>
<td class="Botrule" align="center"><p class="First">1000</p></td>
<td class="Botrule" align="center"><p class="First">NDC 0338-0147-04</p></td>
</tr>
</tbody>
</table>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-0bc58718-fdff-4fff-843d-5d2c4ba31575"></a><a name="section-11"></a><p></p>
<h1>DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER</h1>
<p class="First">For information on Risk of <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">Air Embolism</span> – See <a href="#i4i_precautions_id_bcd03a97-30c7-40fd-88cf-0f355585caa9">PRECAUTIONS</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-ad11925c-9d1b-42e3-8032-577f19b4bd1c"></a><a name="section-11.1"></a><p></p>
<h2>To Open</h2>
<p class="First">Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. If supplemental medication is desired, follow directions below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-3209f917-9168-4a23-a830-ae3e6ec10c72"></a><a name="section-11.2"></a><p></p>
<h2>Preparation for Administration</h2>
<dl>
<dt>1.</dt>
<dd>Suspend container from eyelet support. </dd>
<dt>2.</dt>
<dd>Remove protector from outlet port at bottom of container. </dd>
<dt>3.</dt>
<dd>Attach administration set. Refer to complete directions accompanying set.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-3468874e-d3d4-4af7-ab23-dc2764d18d16"></a><a name="section-11.3"></a><p></p>
<h2>To Add Medication </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-c986ee03-b3c8-44cd-8ed5-e7458ff9e76d"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">To add medication before solution administration</span></h3>
<dl>
<dt>1.</dt>
<dd>Prepare medication site. </dd>
<dt>2.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture medication port and inject. </dd>
<dt>3.</dt>
<dd>Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_inv-9a76e4d4-cf58-4438-97e5-f27d105ba402"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">To add medication during solution administration</span></h3>
<dl>
<dt>1.</dt>
<dd>Close clamp on the set. </dd>
<dt>2.</dt>
<dd>Prepare medication site. </dd>
<dt>3.</dt>
<dd>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. </dd>
<dt>4.</dt>
<dd>Remove container from IV pole and/or turn to an upright position. </dd>
<dt>5.</dt>
<dd>Evacuate both ports by squeezing them while container is in the upright position. </dd>
<dt>6.</dt>
<dd>Mix solution and medication thoroughly. </dd>
<dt>7.</dt>
<dd>Return container to in use position and continue administration.</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ae2c2e7-0cea-43e6-a09d-726b33e4f661"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation <br></span>Deerfield, IL 60015 USA <br>Printed in USA </p>
<p>07-19-72-500</p>
<p>Rev. February 2015</p>
<p>Baxter, Plasma-Lyte, Viaflex, and PL 146 are trademarks of <br>Baxter International Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_17015b00-45c4-4869-9cac-4f1e5a08fa12"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - PACKAGING LABELING</h1>
<div class="Figure">
<a name="id439"></a><img alt="Plasma-Lyte 56 and 5% Dextrose Representative Container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85c08b62-8de0-42d2-8cdc-fe42e6b605d7&amp;name=image-02.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p class="First">Container Label </p>
<p>LOT<br>EXP<br><span class="Bold">2B2574</span><br><span class="Bold">NDC 0338-0147-04</span></p>
<p><span class="Bold">PLASMA-LYTE 56</span><br><span class="Bold">and 5% Dextrose</span><br><span class="Bold">Injection</span><br><span class="Bold">(Multiple Electrolytes and</span><br><span class="Bold">Dextrose Injection Type 1 USP)</span></p>
<p><span class="Bold">1000 mL</span></p>
<p>Each 100 mL contains 5 g Dextrose Hydrous USP 234 mg <br>Sodium Chloride USP 128 mg Potassium Acetate USP <br>32 mg Magnesium Acetate Tetrahydrate pH adjusted with <br>Hydrochloric Acid ph 5.0 (4.0 to 6.5) mEq/L <br>Sodium 40 Potassium 13 Magnesium 3 Chloride 40 <br>Acetate 16 Osmolarity 363 mOsmol/L (calc) Sterile <br>Nonpyrogenic Single dose container Additives may be <br>incompatible Consult with pharmacist if available When <br>introducing additives use aseptic technique Mix thoroughly <br>Do not store Dosage Intravenously as directed by a <br>physician See directions Cautions Squeeze and inspect <br>inner bag which maintains product <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> Discard if leaks <br>are found Must not be used in series connections Do not <br>administer simultaneously with blood Do not use unless <br>solution is clear <span class="Bold">Rx Only </span>Store unit in moisture barrier <br>overwrap at room temperature (25°C/77°F) until ready to <br>use Avoid excessive heat See insert</p>
<p>VIAFLEX container<br>PL 146 plastic</p>
<p>Baxter PLASMA-LYTE VIAFLEX and PL 146 are<br>trademarks of Baxter Internatonal Inc.</p>
<p>For product information 1-800-933-0303</p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p>Made in USA </p>
<div class="Figure">
<a name="id489"></a><img alt="Representative Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85c08b62-8de0-42d2-8cdc-fe42e6b605d7&amp;name=image-03.jpg"><p class="MultiMediaCaption">Carton Label </p>
</div>
<p>Carton Label </p>
<p>2B2574X</p>
<p>14-1000 ML</p>
<p>VIAFLEX® CONTAINER</p>
<p>PLASMA-LYTE® 56 &amp; 5% DEX. INJ. (MULTIPLE<br>ELECTROLYTES AND DEX. INJ., TYPE 1, USP</p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE<br>(17) YYMM00 (10) XXXXX</p>
<p>LOT<br>XXXXX</p>
<p>PRIMARY BAR CODE<br>(01) 50303380147040</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLASMA-LYTE 56 AND DEXTROSE 		
					</strong><br><span class="contentTableReg">dextrose monohydrate, sodium chloride, potassium acetate, magnesium acetate tetrahydrate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0147</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROSE MONOHYDRATE</strong> (ANHYDROUS DEXTROSE) </td>
<td class="formItem">DEXTROSE MONOHYDRATE</td>
<td class="formItem">5 g  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION and CHLORIDE ION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">234 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM ACETATE</strong> (POTASSIUM CATION and ACETATE ION) </td>
<td class="formItem">POTASSIUM ACETATE</td>
<td class="formItem">128 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>MAGNESIUM ACETATE TETRAHYDRATE</strong> (MAGNESIUM CATION and ACETATE ION) </td>
<td class="formItem">MAGNESIUM ACETATE TETRAHYDRATE</td>
<td class="formItem">32 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0147-03</td>
<td class="formItem">24  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-0147-04</td>
<td class="formItem">14  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1000 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017385</td>
<td class="formItem">02/01/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">ANALYSIS(0338-0147), LABEL(0338-0147), MANUFACTURE(0338-0147), PACK(0338-0147), STERILIZE(0338-0147)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">194684502</td>
<td class="formItem">ANALYSIS(0338-0147)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>817ac064-377a-447c-bc80-fa145f985ea1</div>
<div>Set id: 85c08b62-8de0-42d2-8cdc-fe42e6b605d7</div>
<div>Version: 6</div>
<div>Effective Time: 20150224</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
